CIK 0001888012
HLVX HilleVax, Inc.
Insider trading from SEC Form 4. Last filing Sep 19, 2025.
In brief
HilleVax, Inc. (HLVX) has 40 SEC Form 4 filings on file from 12 insiders, the latest filed on Sep 19, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
14 open-market trades have been scored at HLVX. The newest: Robert Hershberg (See Remarks) sold $49k of stock on Feb 4, 2025, filed Feb 12, 2025, scored 30 (weak). The largest of the 14 shown: Aditya Kohli (director) sold $336k on Mar 6, 2024, scored 10 (weak), under a 10b5-1 plan. 2 insiders sold within 14 days of each other around Feb 4, 2025.
8 Form 144 notices of planned sales are on file, the latest filed Mar 20, 2024.
Last 90 days
Signals
Open-market buys and sells at HilleVax, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Robert Hershberg See Remarks sell | $49k 26,535 shares | -2% | - | |
| 30Weak | Shane Maltbie Chief Financial Officer sell | $15k 8,291 shares | -9% | - | |
| 20Weak | Aditya Kohli director sell | $986M 18,000 shares | -2% | - | |
| 10Weak | Aditya Kohli director sell | $336k 18,000 shares | -2% | - | |
| 23Weak | Aditya Kohli director sell | $269k 18,000 shares | -2% | - | |
| 19Weak | Aditya Kohli director sell | $92k 6,000 shares | -1% | - | |
| 37Weak | Astrid Borkowski Chief Medical Officer sell | $59k 3,933 shares | -2% | - | |
| 41Moderate | Robert Hershberg See Remarks sell | $173k 11,597 shares | -1% | - | |
| 44Moderate | Shane Maltbie Chief Financial Officer sell | $53k 3,576 shares | -8% | - | |
| 41Moderate | Aditya Kohli director sell | $132k 8,866 shares | -1% | - | |
| 26Weak | Astrid Borkowski Chief Medical Officer sell | $155k 10,000 shares | -6% | - | |
| 34Weak | Astrid Borkowski Chief Medical Officer sell | $287k 20,000 shares | -10% | - | |
| 26Weak | Astrid Borkowski Chief Medical Officer sell | $140k 10,000 shares | -5% | - | |
| 23Weak | Astrid Borkowski Chief Medical Officer sell | $65k 5,000 shares | -2% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 20, 2024 | ADITYA KOHLI Director, Officer | 54,000 0.11% of outstanding | $941k | Mar 20, 2024 | $907k |
| Feb 12, 2024 | ADITYA KOHLI Director, Officer | 54,000 0.11% of outstanding | $810k | Feb 12, 2024 | none |
| Jan 22, 2024 | HERSHBERG ROBERT Officer, Director | 72,000 0.15% of outstanding | $1.0M | Jan 22, 2024 | none |
| Dec 18, 2023 | Astrid Borkowski Officer | 10,000 0.02% of outstanding | $155k | Dec 15, 2023 | none |
| Dec 5, 2023 | Astrid Borkowski Officer | 10,000 0.02% of outstanding | $142k | Dec 1, 2023 | none |
| Dec 5, 2023 | Astrid Borkowski Officer | 10,000 0.02% of outstanding | $145k | Dec 4, 2023 | none |
| Nov 27, 2023 | Borkowski Astrid Officer | 5,000 0.01% of outstanding | $65k | Nov 8, 2023 | none |
| Nov 27, 2023 | Borkowski Astrid Officer | 10,000 0.02% of outstanding | $140k | Nov 17, 2023 | none |
Transactions
The newest 50 of 58 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 17, 2025 | Takeda Pharmaceutical Co Ltd owner | UTender of shares Common Stockindirect: See Explanation of Responses | -6,724,000 | $1.95 | $13M | 0 | Sep 19, 2025 |
| Sep 17, 2025 | Nanette Cocero director | UTender of shares Common Stock | -17,199 | - | - | 0 | Sep 17, 2025 |
| Sep 17, 2025 | Shane Maltbie Chief Financial Officer | UTender of shares Common Stock | -83,738 | - | - | 0 | Sep 17, 2025 |
| Sep 17, 2025 | Gary Dubin director | UTender of shares Common Stock | -17,199 | - | - | 0 | Sep 17, 2025 |
| Sep 17, 2025 | Patrick J Heron director, owner | UTender of shares Common Stockindirect: By Frazier Life Sciences X, L.P. | -8,535,337 | $1.95 | $17M | 0 | Sep 17, 2025 |
| Sep 17, 2025 | Robert Hershberg President and CEO | UTender of shares Common Stock | -1,101,498 | - | - | 0 | Sep 17, 2025 |
| Sep 17, 2025 | Aditya Kohli director | UTender of shares Common Stock | -698,171 | - | - | 0 | Sep 17, 2025 |
| Sep 17, 2025 | Shelley Chu director | UTender of shares Common Stock | -17,199 | - | - | 0 | Sep 17, 2025 |
| Sep 17, 2025 | Julie L. Gerberding director | UTender of shares Common Stock | -59,224 | - | - | 0 | Sep 17, 2025 |
| Sep 17, 2025 | Jaime Sepulveda director | UTender of shares Common Stock | -59,224 | - | - | 0 | Sep 17, 2025 |
| Sep 17, 2025 | Jeryl L Hilleman director | UTender of shares Common Stock | -59,224 | - | - | 0 | Sep 17, 2025 |
| Sep 17, 2025 | Patrick J Heron director, owner | UTender of shares Common Stockindirect: By Patrick J. Heron | -17,199 | $1.95 | $34k | 0 | Sep 17, 2025 |
| Jun 23, 2025 | Aditya Kohli director | AGrant or award Common Stock | +17,199 | $0.00 | $0 | 698,171 | Jun 25, 2025 |
| Jun 23, 2025 | Jeryl L Hilleman director | AGrant or award Common Stock | +17,199 | $0.00 | $0 | 59,224 | Jun 25, 2025 |
| Jun 23, 2025 | Patrick J Heron director | AGrant or award Common Stock | +17,199 | $0.00 | $0 | 17,199 | Jun 25, 2025 |
| Jun 23, 2025 | Jaime Sepulveda director | AGrant or award Common Stock | +17,199 | $0.00 | $0 | 59,224 | Jun 25, 2025 |
| Jun 23, 2025 | Nanette Cocero director | AGrant or award Common Stock | +17,199 | $0.00 | $0 | 17,199 | Jun 25, 2025 |
| Jun 23, 2025 | Julie L. Gerberding director | AGrant or award Common Stock | +17,199 | $0.00 | $0 | 59,224 | Jun 25, 2025 |
| Jun 23, 2025 | Shelley Chu director | AGrant or award Common Stock | +17,199 | $0.00 | $0 | 17,199 | Jun 25, 2025 |
| Jun 23, 2025 | Gary Dubin director | AGrant or award Common Stock | +17,199 | $0.00 | $0 | 17,199 | Jun 25, 2025 |
| Jun 6, 2024 | Shelley Chu director | AGrant or award Stock Optionderivative | +22,500 | $0.00 | $0 | 22,500 | Apr 30, 2025 |
| Jun 6, 2024 | Nanette Cocero director | AGrant or award Stock Optionderivative | +22,500 | $0.00 | $0 | 22,500 | Apr 30, 2025 |
| Jun 6, 2024 | Julie L. Gerberding director | AGrant or award Stock Optionderivative | +22,500 | $0.00 | $0 | 22,500 | Apr 30, 2025 |
| Jun 6, 2024 | Jeryl L Hilleman director | AGrant or award Stock Optionderivative | +22,500 | $0.00 | $0 | 22,500 | Apr 30, 2025 |
| Jun 6, 2024 | Patrick J Heron director | AGrant or award Stock Optionderivative | +22,500 | $0.00 | $0 | 22,500 | Apr 30, 2025 |
| Jun 6, 2024 | Jaime Sepulveda director | AGrant or award Stock Optionderivative | +22,500 | $0.00 | $0 | 22,500 | Apr 30, 2025 |
| Feb 4, 2025 | Robert Hershberg See Remarks | SOpen-market sale Common Stock | -14,634 | $1.89 | $28k | 1,113,399 | Feb 12, 2025 |
| Feb 4, 2025 | Shane Maltbie Chief Financial Officer | SOpen-market sale Common Stock | -3,946 | $1.89 | $7,458 | 84,232 | Feb 12, 2025 |
| Feb 11, 2025 | Robert Hershberg See Remarks | SOpen-market sale Common Stock | -11,901 | $1.76 | $21k | 1,101,498 | Feb 12, 2025 |
| Feb 11, 2025 | Shane Maltbie Chief Financial Officer | SOpen-market sale Common Stock | -4,345 | $1.76 | $7,659 | 79,887 | Feb 12, 2025 |
| Mar 18, 2024 | Aditya Kohli director | SOpen-market sale Common Stock10b5-1 | -6,000 | $17.66 | $106k | 819,776 | Mar 20, 2024 |
| Mar 19, 2024 | Aditya Kohli director | SOpen-market sale Common Stock10b5-1 | -6,000 | $17.42 | $104k | 813,776 | Mar 20, 2024 |
| Mar 20, 2024 | Aditya Kohli director | SOpen-market sale Common Stock10b5-1 | -6,000 | $164,221.00 | $985M | 807,776 | Mar 20, 2024 |
| Mar 6, 2024 | Aditya Kohli director | SOpen-market sale Common Stock10b5-1 | -6,000 | $18.95 | $114k | 837,776 | Mar 8, 2024 |
| Mar 7, 2024 | Aditya Kohli director | SOpen-market sale Common Stock10b5-1 | -6,000 | $18.37 | $110k | 831,776 | Mar 8, 2024 |
| Mar 8, 2024 | Aditya Kohli director | SOpen-market sale Common Stock10b5-1 | -6,000 | $18.66 | $112k | 825,776 | Mar 8, 2024 |
| Feb 20, 2024 | Aditya Kohli director | SOpen-market sale Common Stock10b5-1 | -6,000 | $14.88 | $89k | 855,776 | Feb 22, 2024 |
| Feb 21, 2024 | Aditya Kohli director | SOpen-market sale Common Stock10b5-1 | -6,000 | $14.92 | $89k | 849,776 | Feb 22, 2024 |
| Feb 22, 2024 | Aditya Kohli director | SOpen-market sale Common Stock10b5-1 | -6,000 | $15.05 | $90k | 843,776 | Feb 22, 2024 |
| Feb 12, 2024 | Aditya Kohli director | SOpen-market sale Common Stock10b5-1 | -6,000 | $15.32 | $92k | 861,776 | Feb 14, 2024 |
| Feb 8, 2024 | Astrid Borkowski Chief Medical Officer | SOpen-market sale Common Stock | -3,933 | $14.93 | $59k | 161,260 | Feb 12, 2024 |
| Feb 8, 2024 | Robert Hershberg See Remarks | SOpen-market sale Common Stock | -11,597 | $14.93 | $173k | 953,831 | Feb 12, 2024 |
| Feb 8, 2024 | Shane Maltbie Chief Financial Officer | SOpen-market sale Common Stock | -3,576 | $14.93 | $53k | 40,656 | Feb 12, 2024 |
| Feb 8, 2024 | Aditya Kohli director | SOpen-market sale Common Stock | -8,866 | $14.93 | $132k | 812,878 | Feb 12, 2024 |
| Feb 8, 2024 | Astrid Borkowski Chief Medical Officer | AGrant or award Common Stock | +53,632 | $0.00 | $0 | 214,892 | Feb 12, 2024 |
| Feb 8, 2024 | Robert Hershberg See Remarks | AGrant or award Common Stock | +174,202 | $0.00 | $0 | 1,128,033 | Feb 12, 2024 |
| Feb 8, 2024 | Aditya Kohli director | AGrant or award Common Stock | +54,898 | $0.00 | $0 | 867,776 | Feb 12, 2024 |
| Feb 8, 2024 | Shane Maltbie Chief Financial Officer | AGrant or award Common Stock | +47,522 | $0.00 | $0 | 88,178 | Feb 12, 2024 |
| Feb 8, 2024 | Astrid Borkowski Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +69,852 | $0.00 | $0 | 69,852 | Feb 12, 2024 |
| Feb 8, 2024 | Robert Hershberg See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +226,885 | $0.00 | $0 | 226,885 | Feb 12, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Astrid BorkowskiChief Medical Officer
- Shelley Chudirector
- Nanette Cocerodirector
- Gary Dubindirector
- Julie L. Gerberdingdirector
- Robert HershbergSee Remarks
- Jeryl L Hillemandirector
- Patrick J Herondirector, owner
- Aditya Kohlidirector
- Shane MaltbieChief Financial Officer
- Jaime Sepulvedadirector
- Takeda Pharmaceutical Co Ltdowner
Questions about HLVX
Answered from the filings on this page, as of the latest one.
Are insiders buying HLVX?
No. In the last 90 days no insider at HilleVax, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade HLVX on the open market?
Robert Hershberg (See Remarks) sold $49k of HLVX on Feb 4, 2025 and filed the Form 4 on Feb 12, 2025. InsiderTell scored 30 (weak), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at HilleVax, Inc.?
12 people have filed a Form 4 at HilleVax, Inc., among them Astrid Borkowski (Chief Medical Officer), Shelley Chu (director), Nanette Cocero (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.